response to ursodeoxycholic acid (UDCA). The designation was granted to Genfit. In June 2024, the US FDA granted accelerated approval to elafibranor. The...
14 KB (888 words) - 08:34, 28 October 2024
(USA, 2014) In Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), Genfit (FR, 2004) In Neurology (MS): GENEURO (CH, 2014) In Oncology: CTI BIOPHARMA...
13 KB (1,176 words) - 01:59, 13 October 2024
disorders at all stages of chronic kidney disease. Versantis AG was acquired by Genfit in Sep-2022 including their team of experts to complements their research...
11 KB (1,067 words) - 23:09, 30 July 2024